全文获取类型
收费全文 | 19434篇 |
免费 | 1237篇 |
国内免费 | 611篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 339篇 |
妇产科学 | 109篇 |
基础医学 | 2609篇 |
口腔科学 | 250篇 |
临床医学 | 2014篇 |
内科学 | 3871篇 |
皮肤病学 | 166篇 |
神经病学 | 1548篇 |
特种医学 | 281篇 |
外国民族医学 | 3篇 |
外科学 | 839篇 |
综合类 | 3089篇 |
现状与发展 | 2篇 |
预防医学 | 559篇 |
眼科学 | 119篇 |
药学 | 4365篇 |
3篇 | |
中国医学 | 583篇 |
肿瘤学 | 490篇 |
出版年
2024年 | 6篇 |
2023年 | 161篇 |
2022年 | 250篇 |
2021年 | 491篇 |
2020年 | 455篇 |
2019年 | 469篇 |
2018年 | 442篇 |
2017年 | 503篇 |
2016年 | 527篇 |
2015年 | 635篇 |
2014年 | 1169篇 |
2013年 | 1372篇 |
2012年 | 1146篇 |
2011年 | 1286篇 |
2010年 | 1044篇 |
2009年 | 987篇 |
2008年 | 981篇 |
2007年 | 966篇 |
2006年 | 869篇 |
2005年 | 833篇 |
2004年 | 661篇 |
2003年 | 619篇 |
2002年 | 494篇 |
2001年 | 470篇 |
2000年 | 408篇 |
1999年 | 356篇 |
1998年 | 298篇 |
1997年 | 321篇 |
1996年 | 277篇 |
1995年 | 266篇 |
1994年 | 280篇 |
1993年 | 261篇 |
1992年 | 239篇 |
1991年 | 210篇 |
1990年 | 203篇 |
1989年 | 178篇 |
1988年 | 162篇 |
1987年 | 153篇 |
1986年 | 140篇 |
1985年 | 149篇 |
1984年 | 108篇 |
1983年 | 94篇 |
1982年 | 79篇 |
1981年 | 77篇 |
1980年 | 61篇 |
1979年 | 55篇 |
1978年 | 29篇 |
1977年 | 12篇 |
1976年 | 10篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
43.
目的:探讨冠心Ⅲ号对缺血性心肌病机体氧化应激及心肌组织纤维化的影响。方法:选取2017年11月至2019年5月广州中医药大学深圳医院收治的ICM患者100例作为研究对象,按照住院号单双分为对照组和观察组,每组50例。对照组常规西医治疗,观察组在对照组基础上加用冠心Ⅲ号治疗,均治疗4周,观察治疗前后NO、SOD、BNP和心肌纤维化指标变化。结果:1)2组患者治疗4周后ET、CRP、BNP、LVEDd、、透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)较治疗前比较均显著降低,NO、SOD、LVEF、△FS、E/A值及SV较治疗前均显著升高,组内比较差异有统计学意义(P<0.01),且观察组显著优于对照组(P<0.01);2)治疗前后2组全血高切、全血中切、全血低切、血浆黏度、红细胞压积、纤维蛋白原差异无统计学意义(P>0.05);3)对照组不良反应率合计12%,观察组为8%,比较差异无统计学意义(P>0.05)。结论:冠心Ⅲ号可通过提高NO、SOD,降低BNP和心肌纤维化,促进血液循环,从而改善心功能,防治ICM。 相似文献
44.
《Archives of Cardiovascular Diseases》2020,113(8-9):551-563
Central illustration. Summary of strategies to improve atrial fibrillation (AF) ablation outcomes in obese patients. BMI: body mass index; BS: bariatric surgery; CT: computed tomography; CV: cardiovascular; EAM: electro-anatomical mapping system; EAT: epicardial adipose tissue; MRI: magnetic resonance imaging; NOAC: non-vitamin K antagonist oral anticoagulant; PAF: paroxysmal atrial fibrillation; TOE: transoesophageal echocardiography; TTE: transthoracic echocardiography; US: ultrasound; VKA: vitamin K antagonist. 相似文献
45.
46.
47.
采用离子交联法制备壳聚糖纳米粒(CS-NPs)载体,并以粒径和多分散系数(PDI)为主要评价指标优化了工艺参数。通过文献检索,筛选出结核分枝杆菌复合群(Mycobacterium tuberculosis complex,MTC)标准强菌株H37Rv的保护性抗原蛋白Rv0180c(GLDKNKFDIRVVSPDEARRLY),经异硫氰荧光素(FITC)标记后载入优化的空白CS-NPs中,获得结核多肽壳聚糖纳米粒(Pep-CS-NPs)。所得空白CS-NPs的平均粒径、PDI和ζ电位分别为(148.13±2.24)nm、0.197±0.013和(+18.00±0.89)mV;4℃放置28 d,粒径未见显著增大。Pep-CS-NPs的平均粒径、PDI和ζ电位分别为(186.93±8.80)nm、0.254±0.014和(+12.07±1.68)mV,包封率和载药量为(45.20±2.95)%和(12.92±1.12)%。体外释放结果表明,Pep-CS-NPs缓慢释放多肽,48 h累积释放率为56.6%。本试验表明,离子交联法制备载多肽CS-NPs的工艺简便稳定、条件温和,所得制品粒径大小适宜、分布均匀,且具有明显缓释作用,有望作为治疗结核病的新型疫苗。 相似文献
48.
内伤咳嗽以肺失宣肃、肺气上逆为基本病机。“苦辛通降助肺法”即借助药物气味的升降作用以使肺气宣降复常的治法,用于治疗内伤咳嗽可通过苦辛配伍来助肺宣降、调节气机。张之文教授为全国温病学泰斗,提出以“苦辛通降助肺法”治疗内伤咳嗽,临床效果显著。本研究以张老医案为基础,通过数据挖掘来管窥“苦辛通降助肺法”治疗内伤咳嗽的应用规律,为内伤咳嗽的治疗提供新的思路和方法。 相似文献
49.
Ewelina Jasic-Szpak Thomas H. Marwick Erwan Donal Monika Przewlocka-Kosmala Quan Huynh Anna Gozdzik Anna K. Woznicka Ewa A. Jankowska Piotr Ponikowski Wojciech Kosmala 《JACC: Cardiovascular Imaging》2021,14(1):131-144
ObjectivesThis study sought to identify the factors associated with incident atrial fibrillation (AF) in a well-characterized heart failure with preserved ejection fraction (HFpEF) population, with special focus on left atrial (LA) strain.BackgroundAF is associated with HFpEF, with adverse consequences. Effective risk evaluation might allow the initiation of protective strategies.MethodsClinical evaluation and echocardiography, including measurements of peak atrial longitudinal strain (PALS), peak atrial contraction strain (PACS), and LA volume index (LAVI), were obtained in 170 patients with symptomatic HFpEF (mean age, 65 ± 8 years), free of baseline AF. AF was identified by standard 12-lead electrocardiogram, review of relevant medical records (including Holter documentation), and surveillance with a portable single-lead electrocardiogram device over 2 weeks. Results were validated in the 103 patients with HFpEF from the Karolinska-Rennes (KaRen) study.ResultsOver a median follow-up of 49 months, incident AF was identified in 39 patients (23%). Patients who developed AF were older; had higher clinical risk scores, brain natriuretic peptide, creatinine, LAVI, and LV mass; lower LA strain and exercise capacity; and more impaired LV diastolic function. PACS, PALS, and LAVI were the most predictive parameters for AF (area under receiver-operating characteristic curve: 0.76 for PACS, 0.71 for PALS, and 0.72 for LAVI). Nested Cox regression models showed that the predictive value of PACS and PALS was independent from and incremental to clinical data, LAVI, and E/e’ ratio. Classification and regression trees analysis identified PACS ≤12.7%, PALS ≤29.4%, and LAVI >34.3 ml/m2 as discriminatory nodes for AF, with a 33-fold greater hazard of AF (p < 0.001) in patients categorized as high risk. The classification and regression trees algorithm discriminated high and low AF risk in the validation cohort.ConclusionsPACS and PALS provide incremental predictive information about incident AF in HFpEF. The inclusion of these LA strain components to the diagnostic algorithm may help guide screening and further monitoring for AF risk in this population. 相似文献
50.
Maria Rinzivillo Ilaria De Felice Ludovica Magi Bruno Annibale Francesco Panzuto 《Journal of gastrointestinal oncology.》2021,12(2):845
BackgroundIn the last decades, the incidence of neuroendocrine neoplasia (NEN) increased from 1 to 5 new diagnoses/100,000 persons/year. The synthetic somatostatin analogues (SSAs) represent the first-choice treatment for both functionally active and inactive gastro-enteric-pancreatic NEN. This systematic review examines the role of octreotide long-acting release (LAR) in combination with other therapies for NEN management.MethodsPrimary outcomes were the disease control rate and the progression free survival (PFS), defined as the time between treatment initiation and progression of disease. Secondary outcomes were overall survival (OS) and safety.ResultsThis systematic review identified 13 studies, concerning the use of octreotide LAR in association with other therapies in advanced NENs and included 1,206 patients. Patients were treated with octreotide LAR in combination with other drugs, mainly with everolimus (404 patients, 35%), but even with Peptide Receptor Radionuclide Therapy, bevacizumab, interferon or fluoride-derivatives. Disease control was observed in 85% cases with SSAs in combination with other therapies; PFS ranged from 15 to 16.4 months and OS from 25 to 61.9 months. SSAs are very well tolerated drugs, with few side effects which are usually mild, not requiring drug withdrawn.ConclusionsThe review summarizes the effectiveness and available safety data on octreotide LAR in combination with other therapies in patients with NEN and may provide suggestions to address the therapeutic strategy. Further comparative head-to-head studies are needed to understand which is the best combination treatment for patients with progressive NEN after failure of first-line therapy. 相似文献